Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Protein phosphatase 5 and the tumor suppressor p53 down-regulate each other's activities in mice.

Wang J, Shen T, Zhu W, Dou L, Gu H, Zhang L, Yang Z, Chen H, Zhou Q, Sánchez ER, Field LJ, Mayo LD, Xie Z, Xiao D, Lin X, Shou W, Yong W.

J Biol Chem. 2018 Nov 23;293(47):18218-18229. doi: 10.1074/jbc.RA118.004256. Epub 2018 Sep 27.

PMID:
30262665
2.

The proto-oncogene function of Mdm2 in bone.

Olivos DJ 3rd, Perrien DS, Hooker A, Cheng YH, Fuchs RK, Hong JM, Bruzzaniti A, Chun K, Eischen CM, Kacena MA, Mayo LD.

J Cell Biochem. 2018 Nov;119(11):8830-8840. doi: 10.1002/jcb.27133. Epub 2018 Jul 16.

PMID:
30011084
3.

Nuclear PTEN enhances the maturation of a microRNA regulon to limit MyD88-dependent susceptibility to sepsis.

Sisti F, Wang S, Brandt SL, Glosson-Byers N, Mayo LD, Son YM, Sturgeon S, Filgueiras L, Jancar S, Wong H, Dela Cruz CS, Andrews N, Alves-Filho JC, Cunha FQ, Serezani CH.

Sci Signal. 2018 May 1;11(528). pii: eaai9085. doi: 10.1126/scisignal.aai9085.

PMID:
29717063
4.

Mutant and wild-type p53 form complexes with p73 upon phosphorylation by the kinase JNK.

Wolf ER, McAtarsney CP, Bredhold KE, Kline AM, Mayo LD.

Sci Signal. 2018 Apr 3;11(524). pii: eaao4170. doi: 10.1126/scisignal.aao4170.

PMID:
29615516
5.

Genotoxic stresses promote clonal expansion of hematopoietic stem cells expressing mutant p53.

Chen S, Gao R, Yao C, Kobayashi M, Liu SZ, Yoder MC, Broxmeyer H, Kapur R, Boswell HS, Mayo LD, Liu Y.

Leukemia. 2018 Mar;32(3):850-854. doi: 10.1038/leu.2017.325. Epub 2017 Nov 16. No abstract available.

6.

The fate of murine double minute X (MdmX) is dictated by distinct signaling pathways through murine double minute 2 (Mdm2).

Hauck PM, Wolf ER, Olivos DJ 3rd, McAtarsney CP, Mayo LD.

Oncotarget. 2017 Nov 6;8(61):104455-104466. doi: 10.18632/oncotarget.22320. eCollection 2017 Nov 28.

7.

Early-Stage Metastasis Requires Mdm2 and Not p53 Gain of Function.

Hauck PM, Wolf ER, Olivos DJ 3rd, Batuello CN, McElyea KC, McAtarsney CP, Cournoyer RM, Sandusky GE, Mayo LD.

Mol Cancer Res. 2017 Nov;15(11):1598-1607. doi: 10.1158/1541-7786.MCR-17-0174. Epub 2017 Aug 7.

8.

Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness.

Olivos DJ, Mayo LD.

Int J Mol Sci. 2016 Nov 26;17(12). pii: E1982. Review.

9.

Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.

Wang H, Cai S, Bailey BJ, Reza Saadatzadeh M, Ding J, Tonsing-Carter E, Georgiadis TM, Zachary Gunter T, Long EC, Minto RE, Gordon KR, Sen SE, Cai W, Eitel JA, Waning DL, Bringman LR, Wells CD, Murray ME, Sarkaria JN, Gelbert LM, Jones DR, Cohen-Gadol AA, Mayo LD, Shannon HE, Pollok KE.

J Neurosurg. 2017 Feb;126(2):446-459. doi: 10.3171/2016.1.JNS152513. Epub 2016 May 13.

10.

Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model.

Tonsing-Carter E, Bailey BJ, Saadatzadeh MR, Ding J, Wang H, Sinn AL, Peterman KM, Spragins TK, Silver JM, Sprouse AA, Georgiadis TM, Gunter TZ, Long EC, Minto RE, Marchal CC, Batuello CN, Safa AR, Hanenberg H, Territo PR, Sandusky GE, Mayo LD, Eischen CM, Shannon HE, Pollok KE.

Mol Cancer Ther. 2015 Dec;14(12):2850-63. doi: 10.1158/1535-7163.MCT-15-0237. Epub 2015 Oct 22.

11.

Src phosphorylation converts Mdm2 from a ubiquitinating to a neddylating E3 ligase.

Batuello CN, Hauck PM, Gendron JM, Lehman JA, Mayo LD.

Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1749-54. doi: 10.1073/pnas.1416656112. Epub 2015 Jan 26.

12.

Ferroxitosis: a cell death from modulation of oxidative phosphorylation and PKM2-dependent glycolysis in melanoma.

Lakhter AJ, Hamilton J, Dagher PC, Mukkamala S, Hato T, Dong XC, Mayo LD, Harris RA, Shekhar A, Ivan M, Brustovetsky N, Naidu SR.

Oncotarget. 2014 Dec 30;5(24):12694-703.

13.

Signaling pathways involved in megakaryocyte-mediated proliferation of osteoblast lineage cells.

Cheng YH, Streicher DA, Waning DL, Chitteti BR, Gerard-O'Riley R, Horowitz MC, Bidwell JP, Pavalko FM, Srour EF, Mayo LD, Kacena MA.

J Cell Physiol. 2015 Mar;230(3):578-86. doi: 10.1002/jcp.24774.

14.

Serdemetan antagonizes the Mdm2-HIF1α axis leading to decreased levels of glycolytic enzymes.

Lehman JA, Hauck PM, Gendron JM, Batuello CN, Eitel JA, Albig A, Kadakia MP, Mayo LD.

PLoS One. 2013 Sep 6;8(9):e74741. doi: 10.1371/journal.pone.0074741. eCollection 2013.

15.

Temozolomide-mediated DNA methylation in human myeloid precursor cells: differential involvement of intrinsic and extrinsic apoptotic pathways.

Wang H, Cai S, Ernstberger A, Bailey BJ, Wang MZ, Cai W, Goebel WS, Czader MB, Crean C, Suvannasankha A, Shokolenkoc I, Wilson GL, Baluyut AR, Mayo LD, Pollok KE.

Clin Cancer Res. 2013 May 15;19(10):2699-709. doi: 10.1158/1078-0432.CCR-12-2671. Epub 2013 Mar 27.

16.

Pyk2 regulates megakaryocyte-induced increases in osteoblast number and bone formation.

Cheng YH, Hooker RA, Nguyen K, Gerard-O'Riley R, Waning DL, Chitteti BR, Meijome TE, Chua HL, Plett AP, Orschell CM, Srour EF, Mayo LD, Pavalko FM, Bruzzaniti A, Kacena MA.

J Bone Miner Res. 2013 Jun;28(6):1434-45. doi: 10.1002/jbmr.1876.

17.

Integration of DNA damage and repair with murine double-minute 2 (Mdm2) in tumorigenesis.

Lehman JA, Mayo LD.

Int J Mol Sci. 2012 Dec 3;13(12):16373-86. doi: 10.3390/ijms131216373. Review.

18.

Directing p53 to induce autophagy.

Mayo LD.

Cell Cycle. 2012 Sep 15;11(18):3353-4. doi: 10.4161/cc.21849. Epub 2012 Aug 23.

19.

Inauhzin and Nutlin3 synergistically activate p53 and suppress tumor growth.

Zhang Y, Zhang Q, Zeng SX, Zhang Y, Mayo LD, Lu H.

Cancer Biol Ther. 2012 Aug;13(10):915-24. doi: 10.4161/cbt.20844. Epub 2012 Aug 1.

20.

Megakaryocytes regulate expression of Pyk2 isoforms and caspase-mediated cleavage of actin in osteoblasts.

Kacena MA, Eleniste PP, Cheng YH, Huang S, Shivanna M, Meijome TE, Mayo LD, Bruzzaniti A.

J Biol Chem. 2012 May 18;287(21):17257-68. doi: 10.1074/jbc.M111.309880. Epub 2012 Mar 23.

21.

Induction of apoptotic genes by a p73-phosphatase and tensin homolog (p73-PTEN) protein complex in response to genotoxic stress.

Lehman JA, Waning DL, Batuello CN, Cipriano R, Kadakia MP, Mayo LD.

J Biol Chem. 2011 Oct 21;286(42):36631-40. doi: 10.1074/jbc.M110.217620. Epub 2011 Aug 26.

22.

ΔNp63α regulates keratinocyte proliferation by controlling PTEN expression and localization.

Leonard MK, Kommagani R, Payal V, Mayo LD, Shamma HN, Kadakia MP.

Cell Death Differ. 2011 Dec;18(12):1924-33. doi: 10.1038/cdd.2011.73. Epub 2011 Jun 3.

23.

Humanized bone marrow mouse model as a preclinical tool to assess therapy-mediated hematotoxicity.

Cai S, Wang H, Bailey B, Ernstberger A, Juliar BE, Sinn AL, Chan RJ, Jones DR, Mayo LD, Baluyut AR, Goebel WS, Pollok KE.

Clin Cancer Res. 2011 Apr 15;17(8):2195-206. doi: 10.1158/1078-0432.CCR-10-1959. Epub 2011 Apr 12.

24.

ATM-dependent IGF-1 induction regulates secretory clusterin expression after DNA damage and in genetic instability.

Goetz EM, Shankar B, Zou Y, Morales JC, Luo X, Araki S, Bachoo R, Mayo LD, Boothman DA.

Oncogene. 2011 Sep 1;30(35):3745-54. doi: 10.1038/onc.2011.92. Epub 2011 Apr 4.

25.

c-Abl phosphorylation of Mdm2 facilitates Mdm2-Mdmx complex formation.

Waning DL, Lehman JA, Batuello CN, Mayo LD.

J Biol Chem. 2011 Jan 7;286(1):216-22. doi: 10.1074/jbc.M110.183012. Epub 2010 Nov 16.

26.

Controlling the Mdm2-Mdmx-p53 Circuit.

Waning DL, Lehman JA, Batuello CN, Mayo LD.

Pharmaceuticals (Basel). 2010 May 18;3(5):1576-1593.

27.

Inactivation of p53 signaling by p73 or PTEN ablation results in a transformed phenotype that remains susceptible to Nutlin-3 mediated apoptosis.

Cipriano R, Patton JT, Mayo LD, Jackson MW.

Cell Cycle. 2010 Apr 1;9(7):1373-9. Epub 2010 Apr 1.

PMID:
20305378
28.

TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer.

Araki S, Eitel JA, Batuello CN, Bijangi-Vishehsaraei K, Xie XJ, Danielpour D, Pollok KE, Boothman DA, Mayo LD.

J Clin Invest. 2010 Jan;120(1):290-302. doi: 10.1172/JCI39194. Epub 2009 Dec 1.

29.

Up-regulation of hepatitis C virus replication and production by inhibition of MEK/ERK signaling.

Ndjomou J, Park IW, Liu Y, Mayo LD, He JJ.

PLoS One. 2009 Oct 16;4(10):e7498. doi: 10.1371/journal.pone.0007498.

30.

Therapeutic considerations for Mdm2: not just a one trick pony.

Lehman JA, Eitel JA, Batuello CN, Mayo LD.

Expert Opin Drug Discov. 2008 Nov;3(11):1309-1321.

31.

Ribosomal protein S3: A multi-functional protein that interacts with both p53 and MDM2 through its KH domain.

Yadavilli S, Mayo LD, Higgins M, Lain S, Hegde V, Deutsch WA.

DNA Repair (Amst). 2009 Oct 2;8(10):1215-24. doi: 10.1016/j.dnarep.2009.07.003. Epub 2009 Aug 4.

32.

Hdm2 is a ubiquitin ligase of Ku70-Akt promotes cell survival by inhibiting Hdm2-dependent Ku70 destabilization.

Gama V, Gomez JA, Mayo LD, Jackson MW, Danielpour D, Song K, Haas AL, Laughlin MJ, Matsuyama S.

Cell Death Differ. 2009 May;16(5):758-69. doi: 10.1038/cdd.2009.6. Epub 2009 Feb 27.

33.

PTEN and p53 are required for hypoxia induced expression of maspin in glioblastoma cells.

Eitel JA, Bijangi-Vishehsaraei K, Saadatzadeh MR, Bhavsar JR, Murphy MP, Pollok KE, Mayo LD.

Cell Cycle. 2009 Mar 15;8(6):896-901. Epub 2009 Mar 21.

PMID:
19221500
34.

Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2.

LaRusch GA, Jackson MW, Dunbar JD, Warren RS, Donner DB, Mayo LD.

Cancer Res. 2007 Jan 15;67(2):450-4.

35.

Hdm2 nuclear export, regulated by insulin-like growth factor-I/MAPK/p90Rsk signaling, mediates the transformation of human cells.

Jackson MW, Patt LE, LaRusch GA, Donner DB, Stark GR, Mayo LD.

J Biol Chem. 2006 Jun 16;281(24):16814-20. Epub 2006 Apr 18.

36.

Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3.

Patton JT, Mayo LD, Singhi AD, Gudkov AV, Stark GR, Jackson MW.

Cancer Res. 2006 Mar 15;66(6):3169-76.

37.

p53 regulates Btk-dependent B cell proliferation but not differentiation.

Schmidt NW, Mayo LD, Donner DB, Kaplan MH.

J Leukoc Biol. 2006 Apr;79(4):852-9. Epub 2006 Feb 3.

PMID:
16461747
38.

Involvement of the ubiquitin pathway in decreasing Ku70 levels in response to drug-induced apoptosis.

Gama V, Yoshida T, Gomez JA, Basile DP, Mayo LD, Haas AL, Matsuyama S.

Exp Cell Res. 2006 Feb 15;312(4):488-99.

PMID:
16368436
39.

Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified.

Mayo LD, Seo YR, Jackson MW, Smith ML, Rivera Guzman J, Korgaonkar CK, Donner DB.

J Biol Chem. 2005 Jul 15;280(28):25953-9. Epub 2005 Apr 20.

40.

Delayed activation of insulin-like growth factor-1 receptor/Src/MAPK/Egr-1 signaling regulates clusterin expression, a pro-survival factor.

Criswell T, Beman M, Araki S, Leskov K, Cataldo E, Mayo LD, Boothman DA.

J Biol Chem. 2005 Apr 8;280(14):14212-21. Epub 2005 Feb 2.

41.

Tumor necrosis factor activates CRE-binding protein through a p38 MAPK/MSK1 signaling pathway in endothelial cells.

Gustin JA, Pincheira R, Mayo LD, Ozes ON, Kessler KM, Baerwald MR, Korgaonkar CK, Donner DB.

Am J Physiol Cell Physiol. 2004 Mar;286(3):C547-55.

42.

Cell type-specific expression of the IkappaB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-kappa B activation.

Gustin JA, Ozes ON, Akca H, Pincheira R, Mayo LD, Li Q, Guzman JR, Korgaonkar CK, Donner DB.

J Biol Chem. 2004 Jan 16;279(3):1615-20. Epub 2003 Oct 29.

44.

The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network.

Mayo LD, Donner DB.

Trends Biochem Sci. 2002 Sep;27(9):462-7. Review.

PMID:
12217521
45.

PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy.

Mayo LD, Dixon JE, Durden DL, Tonks NK, Donner DB.

J Biol Chem. 2002 Feb 15;277(7):5484-9. Epub 2001 Nov 29.

46.

A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus.

Mayo LD, Donner DB.

Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11598-603. Epub 2001 Aug 14.

47.

Vascular endothelial cell growth factor activates CRE-binding protein by signaling through the KDR receptor tyrosine kinase.

Mayo LD, Kessler KM, Pincheira R, Warren RS, Donner DB.

J Biol Chem. 2001 Jul 6;276(27):25184-9. Epub 2001 May 2.

48.

A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1.

Ozes ON, Akca H, Mayo LD, Gustin JA, Maehama T, Dixon JE, Donner DB.

Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4640-5. Epub 2001 Apr 3.

49.

Tumor necrosis factor employs a protein-tyrosine phosphatase to inhibit activation of KDR and vascular endothelial cell growth factor-induced endothelial cell proliferation.

Guo DQ, Wu LW, Dunbar JD, Ozes ON, Mayo LD, Kessler KM, Gustin JA, Baerwald MR, Jaffe EA, Warren RS, Donner DB.

J Biol Chem. 2000 Apr 14;275(15):11216-21.

50.

VRAP is an adaptor protein that binds KDR, a receptor for vascular endothelial cell growth factor.

Wu LW, Mayo LD, Dunbar JD, Kessler KM, Ozes ON, Warren RS, Donner DB.

J Biol Chem. 2000 Mar 3;275(9):6059-62.

Supplemental Content

Support Center